{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-002470","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2022-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.972919+00:00","generated_at":"2026-06-27T02:42:42.658397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TG Therapeutics Q4 net loss $93.3M; UKONIQ revenue $2.3M; FDA partial hold on U2","bullets":["Net loss Q4 2021 $93.3M ($88.2M Q4 2020); full year net loss $348.1M ($279.4M 2020).","Product revenue from UKONIQ net $2.3M in Q4, $6.5M for full year 2021.","Cash, equivalents & securities $350.3M at Dec 31, 2021; funds operations into 2023.","FDA partial clinical hold on U2 (ublituximab + umbralisib) studies in CLL/NHL; ODAC meeting expected March/April 2022.","FDA accepted BLA for ublituximab in RMS (PDUFA Sept 28, 2022); BLA/sNDA for U2 in CLL/SLL pending ODAC."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-002470","json":"https://secwatch.observer/filing/0001558370-22-002470.json","markdown":"https://secwatch.observer/filing/0001558370-22-002470.md","text":"https://secwatch.observer/filing/0001558370-22-002470.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022002470/0001558370-22-002470-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022002470/tgtx-20220301x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T02:42:42.658397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}